Introducing COMIRNATY®, the EU Brand Name for Pfizer & BioNTech's COVID-19 Vaccine, Developed by Brand Institute

▴ Introducing COMIRNATY®, the EU Brand Name for Pfizer & BioNTech's COVID-19 Vaccine, Developed by Brand Institute
Brand Institute, the global leader in pharmaceutical and healthcare-related name development, is proud to announce its role in naming Pfizer and BioNTech's COVID-19 vaccine: COMIRNATY® (koe mir' na tee).

Brand Institute, the global leader in pharmaceutical and healthcare-related name development, is proud to announce its role in naming Pfizer and BioNTech's COVID-19 vaccine: COMIRNATY® (koe mir' na tee). The name was first announced by Swiss regulatory authority, Swissmedic. Shortly after, it was included in the conditional marketing authorization published by the European Medicines Agency (EMA). The approval of the brand name by other global regulatory agencies will follow their respective guidelines, policies, and procedures.

In a joint press release, BioNTech and Pfizer commented on the vaccine's brand name, "The vaccine will be marketed in the EU under the brand name COMIRNATY®, which represents a combination of the terms COVID-19, mRNA, community, and immunity, to highlight the first authorization of a messenger RNA (mRNA) vaccine, as well as the joint global efforts that made this achievement possible with unprecedented rigor and efficiency, and with safety at the forefront, during this global pandemic."

The COVID-19 vaccine's proposed nonproprietary name (pINN), tozinameran (toe zi na' mer an), was also developed by Brand Institute and its wholly-owned subsidiary, Drug Safety Institute. The "proposed" status of the name indicates the standard 4-month comment period before becoming a recommended INN (rINN). The -meran suffix indicates that this is an mRNA vaccine.

"The entire Brand Institute and Drug Safety Institute team is honored to have partnered with two incredible companies, Pfizer and BioNTech, on the development of their COVID-19 vaccine's brand name, COMIRNATY®, and nonproprietary (p-INN) name, tozinameran," said Brand Institute's Chairman and CEO, James L. Dettore. "Naming a product that will have such a profound global impact is humbling, and an opportunity for which we are truly grateful."

With a portfolio of over 3,300 marketed healthcare names for close to 950 clients, Brand Institute is the global leader in pharmaceutical and healthcare-related name development. The company partners on over 75% of pharmaceutical brand and nonproprietary name approvals globally. Drug Safety Institute is comprised of former naming regulatory officials from global government health agencies, including FDA, EMA, Health Canada, American Medical Association (AMA), and the World Health Organization (WHO).

These regulatory experts co-authored the name review guidelines while with their respective agencies, with many responsible for ultimately approving (or rejecting) brand name applications. Now working for a private company, these professionals provide Brand Institute's clients with industry-leading guidance pertaining to drug name safety (i.e., preventing medication errors), packaging, and labeling.

Tags : #BrandInstituteLatestUpdates #PfizerandBioNTechsCOVID-19vaccine #Pfizer #BioNTech #COMIRNATY #Covid-19Vaccine #mRNA #tozinameran #DrugSafetyInstitute #WHO #FDA #EMA #AmericanMedicalAssociation #governmenthealthagencies

Related Stories

02 Apr

DCDC’s $150 Crore Expansion: Can Innovative Clinics End India's Kidney Crisis?

As the healthcare landscape evolves, initiatives like these will determine the future of medical care in the country.

View
01 Mar

India’s Pharma Revolution: Can New Regulatory Reforms Unleash a $42 Billion Industry?

The potential rewards are enormous a robust, efficient, and competitive pharmaceutical industry that not only fuels domestic growth but also serves as a reliable supplier of essential medicines to the world.

View
27 Feb

India’s Newborns Are Dying from Sepsis And No One Is Talking About It

Newborn sepsis is a complex problem that requires innovative solutions. More funding for research on rapid diagnostic tests, alternative treatments is essential to tackle this growing crisis.

View
26 Feb

The Corporate Invasion of Indian Hospitals: What It Means for You

The question remains: will India’s hospital sector continue on its current trajectory and become a global leader in healthcare, or will the challenges of cost, infrastructure, and regulatory hurdles slow down this remarkable journey.

View
24 Feb

The Great Indian Medical Education Paradox: More Seats, Fewer Students, Collapsing System

The NMC’s strategy to allow non-medical faculty and offer incentives for non-clinical PG courses may help in the short term, but a broader shift in how medical education is structured is necessary.

View
24 Feb

The Dark Side of India’s Pharma Boom: How Banned Drugs Found a New Market in West Africa

Stricter regulations, greater transparency, and proactive enforcement are the only ways to ensure that India’s “pharmacy of the world” reputation is built on trust and safety, not on scandals and cover-ups.

View
21 Feb

India vs. Trump’s Pharma Tariff: The Battle Over Affordable Medicine

Indian pharmaceutical companies may suffer short-term financial setbacks, but they hold the upper hand, because the U.S. needs Indian generics more than India needs the U.S. market.

View
19 Feb

Tata’s ₹500-Crore Gamble: Is Healthcare the New Playground for India’s Corporate Giants?

As India’s healthcare sector continues to evolve, corporate giants like Tata are not just participants but key drivers of change.

View
19 Feb

Public Hospitals Go High-Tech: AIIMS Delhi Leads India’s Robotic Surgery Wave

AIIMS sets a precedent for other hospitals across India to follow. If robotic surgery becomes more widespread, the dream of world-class healthcare for all Indians may not be as distant as it once seemed.

View
12 Feb

First in India: Dr. Anshumala Shukla-Kulkarni Becomes Asia’s First Certified Endometriosis Specialist

Delayed diagnosis remains one of the biggest challenges. More awareness campaigns, educational programs, and inclusion of endometriosis can help detect the condition early and improve treatment outcomes.

View

-Advertisements-




Trending Now

The Digital Sleep Thief: How Night-time Screen Addiction is Robbing You of Bed-time RestApril 02, 2025
KKR Launches ‘Knight Bite’ – A Digital Series That Serves Up Food, Fun, and Cricket!April 02, 2025
Crompton rolls out its all new range of Aura, Avancer & Jedi Air Coolers for an effortless summer cooling experienceApril 02, 2025
CARE Hospitals, Hi-Tech City Strengthens Orthopaedics Department with Renowned SurgeonsApril 02, 2025
World Autism Awareness Day: Breaking the Chains of Stigma in IndiaApril 02, 2025
From Scroll to Squint: How Reels Are Reshaping Your VisionApril 02, 2025
Moscow Center for Diagnostics and Telemedicine Receives License for Radiology Residency ProgramApril 02, 2025
CARE Hospitals Launches AI-Powered Non-Invasive Therapy – An innovative modality introduced in Telangana & Andhra PradeshApril 02, 2025
High-Rise Heart Attacks: Are Skyscrapers Turning Survival into a Race Against Time?April 02, 2025
DCDC’s $150 Crore Expansion: Can Innovative Clinics End India's Kidney Crisis?April 02, 2025
Medanta Rolls Out ‘Colon Tunnel on Wheels’ to Drive Awareness on Colorectal Cancer Prevention & Early DetectionApril 01, 2025
Zigly launches 2 pet hospitals, opens 4 new stores; expects ARR to more than double in 1-2 yearsApril 01, 2025
University of Leeds Announces International Masters Regional Scholarships for 2025April 01, 2025
Avantor Recognized with Two Prestigious Awards at Asia-Pacific Biopharma Excellence Awards 2025April 01, 2025
Foundation Stone Laid for Madhav Netralaya Eye Hospital & Research CentreApril 01, 2025
Doomscrolling at Midnight: How Indians Are Sacrificing Sleep for ScreensMarch 31, 2025
Essential Medicines Price Surge: Are Patients Paying the Price?March 31, 2025
Prioritize your health during the holy days of RamzanMarch 31, 2025
Tired of Stomach Cramps? These Simple Foods Can Heal Your GutMarch 31, 2025
Regional growth booming for startups in 2024 - QBO Innovation studyMarch 31, 2025